MTPA and Aquestive Sign a License and Supply Agreement for Exservan (riluzole) to Treat ALS in the US
Shots:
- Aquestive will receive upfront- milestones- royalties on net sales for Exservan (oral film formulation) in the US and will earn revenue pursuant to the exclusive supply agreement
- MTPA to commercialize Exservan in the US while Aquestive will serve as the exclusive sole manufacturer and supplier for the product
- Exservan is an oral film formulation of riluzole- expected to be available in the mid of 2021
Ref: MTPA | Image: Aquestive
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
